Steven W Sutton

US Patent:

6548555, Apr 15, 2003

Filed:

Jan 31, 2000

Appl. No.:

09/495438

Inventors:

William J. Curatolo - Niantic CT
James A. S. Nightingale - Bend OR
Ravi M. Shanker - Groton CT
Steven C. Sutton - Niantic CT

Assignee:

Pfizer Inc - New York NY

International Classification:

A61K 4732

US Classification:

5147724, 424488, 424484, 424486

Abstract:

A composition comprising a basic drug, a drug which forms a zwitterion, or a salt of either entity, admixed with a polymer selected from hydroxypropylmethylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate (CAT), cellulose acetate phthalate (CAP), hydroxypropylcellulose acetate phthalate (HPCAP), hydroxypropylmethylcellulose acetate phthalate (HPMCAP), and methylcellulose acetate phthalate (MCAP). The compositions having improved solubility, hence bioavailability, in the small intestine; Processes for testing such compositions, and methods of using such compositions. The compositions comprise the basic drug, zwitterion, or salt and one or more of the aforementioned polymers. The invention further relates to a method for increasing the bioavailability of a basic or a zwitterionic drug comprising co-administering the basic drug, the zwitterionic drug, or the salt, with one or more of the aforementioned polymers.

US Patent:

20030198674, Oct 23, 2003

Filed:

Jan 23, 2003

Appl. No.:

10/349600

Inventors:

William Curatolo - Niantic CT, US
Steven Sutton - Niantic CT, US
Leah Appel - Bend OR, US

International Classification:

A61K009/22

US Classification:

424/468000

Abstract:

The present invention relates to controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor, (CETPI) methods of using and methods of making same. In particular, it relates to a controlled release form of the CETPI [2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester.

US Patent:

20050038007, Feb 17, 2005

Filed:

Jul 30, 2004

Appl. No.:

10/903433

Inventors:

William Curatolo - Niantic CT, US
Dwayne Friesen - Bend OR, US
Steven Sutton - Niantic CT, US

International Classification:

A61K031/56
A61K031/401
A61K031/366

US Classification:

514171000, 514423000, 514460000, 514548000

Abstract:

A dosage form comprises a cholesteryl ester transfer protein inhibitor in a solubility-improved form and an HMG-CoA reductase inhibitor, wherein the dosage form provides immediate release of the HMG-CoA reductase inhibitor and controlled release of the cholesteryl ester transfer protein inhibitor.

US Patent:

20050049223, Mar 3, 2005

Filed:

Apr 11, 2003

Appl. No.:

10/412399

Inventors:

William Curatolo - Niantic CT, US
James Nightingale - Bend OR, US
Ravi Shanker - Groton CT, US
Steven Sutton - Niantic CT, US

International Classification:

A61K031/716

US Classification:

514057000

Abstract:

A composition comprising a basic drug, a drug which forms a zwitterion, or a salt of either entity, admixed with a polymer selected from hydroxypropylmethylcellulose acetate succinate (HPMCAS), cellulose acetate trimellitate (CAT), cellulose acetate phthalate (CAP), hydroxypropylcellulose acetate phthalate (HPCAP), hydroxypropylmethyl-cellulose acetate phthalate (HPMCAP), and methylcellulose acetate phthalate (MCAP). The compositions having improved solubility, hence bioavailability, in the small intestine; Processes for testing such compositions, and methods of using such compositions. The compositions comprise the basic drug, zwitterion, or salt and one or more of the aforementioned polymers. The invention further relates to a method for increasing the bioavailability of a basic or a zwitterionic drug comprising co-administering the basic drug, the zwitterionic drug, or the salt, with one or more of the aforementioned polymers.

US Patent:

20070190129, Aug 16, 2007

Filed:

Aug 31, 2004

Appl. No.:

10/931143

Inventors:

Imran Ahmed - East Lyme CT, US
Leah Appel - Bend OR, US
Walter Babcock - Bend OR, US
Dwayne Friesen - Bend OR, US
Scott Herbig - East Lyme CT, US
David Lyon - Bend OR, US
Sheri Shamblin - North Stonington CT, US
Ravi Shanker - Groton CT, US
Daniel Smithey - Bend OR, US
Steven Sutton - Niantic CT, US
Avinash Thombre - East Lyme CT, US
Kenneth Waterman - Waterfod CT, US

International Classification:

A61K 9/48
A61K 31/4965

US Classification:

424451000, 514255050

Abstract:

A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.

US Patent:

20100003331, Jan 7, 2010

Filed:

Sep 3, 2009

Appl. No.:

12/261678

Inventors:

Imran Ahmed - East Lyme CT, US
Leah Elizabeth Appel - Bend OR, US
Walter Christian Babcock - Bend OR, US
Dwayne Thomas Friesen - Bend OR, US
Scott Herbig - East Lyme CT, US
David Keith Lyon - Bend OR, US
Sheri L. Shamblin - North Stonington CT, US
Ravi Mysore Shanker - Groton CT, US
Daniel Tod Smithey - Bend OR, US
Steven C. Sutton - Niantic CT, US
Avinash Govind Thombre - East Lyme CT, US
Kenneth C. Waterman - Waterford CT, US
Jaymin C. Shah - Waterford CT, US
Parag Suresh Shah - Groton CT, US
Peter Wisniecki - Coventry CT, US
Dawn Renee Wagner - Groton CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 9/14
A61K 31/501

US Classification:

424489, 51425402, 977906

Abstract:

A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.